Form 4: Dyne Therapeutics Director Receives Stock Option Grant

Director Jason P. Rhodes was granted 35,152 stock options in Dyne Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Jason P. Rhodes received a grant of 35,152 stock options on June 5, 2026.
• The options have an exercise price of $17.04 per share.
• The options are scheduled to vest in full on the earlier of June 5, 2027, or the date of the 2027 Annual Meeting of Stockholders.
• The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest, as he is obligated to transfer economic benefits to Atlas Venture Life Science Advisors, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a routine compensatory filing.

Risks

• The value of the options is subject to market volatility and the future performance of Dyne Therapeutics common stock.

Future Outlook

The options vest in full on June 5, 2027, or the date of the 2027 Annual Meeting of Stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant structure and vesting schedule are consistent with standard equity compensation practices for non-employee directors in mid-cap biotechnology firms.

Related Party Transactions

• The reporting person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer economic benefits from the sale of these shares to Atlas Venture Life Science Advisors, LLC.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director equity alignment.

Next Steps

• Vesting of options on June 5, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

Dyne Therapeutics, DYN, Form 4, Insider Trading, Stock Options, Director Compensation